Albakri Khaled, Abdelwahab Omar Ahmed, Gabra Mohamed Diaa, Nafady Mohamed H, Alabdallat Yasmeen Jamal, Soliman Ahmed, Cadri Shirin, Hanaqtah Balqees, Albazee Ebraheem
Faculty of Medicine, The Hashemite University, Zarqa, Jordan.
Medical Research Group of Egypt, Cairo, Egypt.
Eur Arch Otorhinolaryngol. 2023 Dec;280(12):5167-5176. doi: 10.1007/s00405-023-08172-w. Epub 2023 Aug 18.
COVID-19 vaccines are essential to prevent complications and reduce the burden of SARS-CoV-2. However, these vaccines showed side effects such as fatigue, pain, fever, and rarely hearing loss. In this review, we aim to summarize studies investigating hearing loss following COVID-19 vaccination and try to find the possible association and risk factors for this hazardous complication.
We performed a comprehensive search of five electronic databases (PubMed, Scopus, Web of Science, google scholar, Cochrane) from inception until 9 October 2022. We finally included 16 studies after the first and second scans. We used SPSS to analyze the extracted data.
A total of 630 patients were identified, with a mean age of 57.3. Of the patients, 328 out of 609 vaccinated patients took the Pfizer-BioNTech BNT162b2 vaccine, while 242 (40%) took the Moderna COVID-19 vaccine. The mean time from vaccination to hearing impairment was 6.2, ranging from a few hours to one month after the last dose. The results found a significant difference between vaccine types in terms of incidence and prognosis of the condition, while they showed that the number of doses prior to the onset had no significance.
SNHL has been reported in a small number of people who have received the COVID-19 vaccine, but it is unclear at this time whether the vaccine is directly causing this condition. However, the COVID-19 vaccine has been demonstrated to be safe and effective in preventing illness, and the benefits of vaccination are significant compared to any potential risks.
The protocol of this study was registered on Prospero CRD42022367180.
新冠病毒疫苗对于预防并发症和减轻严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的负担至关重要。然而，这些疫苗显示出一些副作用，如疲劳、疼痛、发热，以及罕见的听力损失。在本综述中，我们旨在总结调查新冠病毒疫苗接种后听力损失的研究，并试图找出这种危险并发症的可能关联和风险因素。
我们对五个电子数据库（PubMed、Scopus、科学网、谷歌学术、考克兰图书馆）进行了全面检索，检索时间从数据库建立至2022年10月9日。经过首次和二次筛选，我们最终纳入了16项研究。我们使用社会科学统计软件包（SPSS）分析提取的数据。
共确定了630名患者，平均年龄为57.3岁。在这些患者中，609名接种疫苗的患者中有328人接种了辉瑞-生物科技公司的BNT162b2疫苗，而242人（40%）接种了莫德纳新冠病毒疫苗。从接种疫苗到听力受损的平均时间为6.2天，范围从最后一剂接种后的几小时到一个月。结果发现，就该病症的发病率和预后而言，不同疫苗类型之间存在显著差异，而结果表明发病前的接种剂量数并无显著意义。
已有少数接种新冠病毒疫苗的人报告出现感音神经性听力损失（SNHL），但目前尚不清楚疫苗是否直接导致这种情况。然而，新冠病毒疫苗已被证明在预防疾病方面是安全有效的，与任何潜在风险相比，接种疫苗的益处是显著的。
本研究方案已在国际前瞻性系统评价注册库（Prospero）注册，注册号为CRD42022367180。
